Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
April 10th, 2018
16.1K views
A protocol for fast CRISPR/Cas9-mediated gene disruption in mouse and human primary hematopoietic cells is described in this article. Cas9-sgRNA ribonucleoproteins are introduced via electroporation with sgRNAs generated through in vitro transcription and commercial Cas9. High editing efficiencies are achieved with limited time and financial cost.
Overview
This article describes a protocol for rapid CRISPR/Cas9-mediated gene disruption in mouse and human primary hematopoietic cells using a ribonucleoprotein approach. The method allows for high editing efficiencies with minimal time and cost.
Key Study Components
Area of Science
- Gene editing
- Hematopoietic cell biology
- CRISPR/Cas9 technology
Background
- CRISPR/Cas9 is a powerful tool for gene disruption.
- Primary hematopoietic cells are crucial for studying hematopoiesis.
- Traditional delivery methods for CRISPR can be toxic or slow.
- This protocol aims to improve efficiency and reduce costs.
Purpose of Study
- To develop a fast and efficient method for gene disruption.
- To investigate the effects of gene loss in hematopoietic progenitor cells.
- To provide a protocol applicable to various cell types.
Methods Used
- Designing single-guide RNAs using CRISPRscan.
- Synthesizing RNA and preparing Cas9-sgRNA ribonucleoprotein complexes.
- Electroporating primary hematopoietic cells with the RNP complexes.
- Assessing gene disruption efficiency using flow cytometry and T7 endonuclease assays.
Main Results
- Achieved approximately 75% loss of target gene expression in HSPCs.
- Demonstrated 98% knockout efficiency in HL-60 AML cell line.
- Showed effective gene disruption in primary human cord blood cells.
- Confirmed engraftment of edited cells in NSG mice.
Conclusions
- The protocol is efficient and can be completed in under a week.
- It is applicable to various hematopoietic cell types.
- Maintaining RNase-free conditions is critical for success.
Frequently Asked Questions
What is the main advantage of this CRISPR method?
It is easy, fast, and cost-effective, allowing for rapid gene disruption.
Can this method be used for other cell types?
Yes, it can be applied to primary T-cells and various hematopoietic cell lines.
How long does the protocol take to complete?
The entire process can be completed in less than a week.
What techniques are used to verify gene disruption?
Flow cytometry and T7 endonuclease assays are used to assess gene editing efficiency.
What precautions should be taken during the protocol?
All surfaces and reagents must be kept RNase-free to ensure successful results.
Executive Industry Relevance
Efficient gene disruption in primary hematopoietic cells enables rapid target validation and mechanistic de-risking in hematologic drug discovery. The ribonucleoprotein CRISPR/Cas9 approach reduces biological uncertainty by delivering high-knockout efficiencies without exogenous DNA, supporting predictive confidence in early target selection. This workflow accelerates discovery timelines for oncology and immunology programs by providing a scalable, cost-effective method for functional genomics in disease-relevant hematopoietic systems.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses through rapid gene knockout in primary murine and human hematopoietic progenitor cells.
- Operational Value: Supports biological de-risking by achieving up to 98% knockout efficiency in AML cell lines and 80% in primary human cord blood HSPCs.
- Strategic Value: Facilitates target confidence and portfolio triage by allowing rapid assessment of gene loss phenotypes in disease-relevant systems.
Screening & Assay Development
- Scientific Value: Prepares validated knockout hematopoietic cells for downstream compound screening and phenotypic assays.
- Operational Value: Delivers standardized, reproducible gene disruption via RNP electroporation with quantitative flow cytometry and T7 endonuclease readouts.
- Strategic Value: Enables scalable platform use across primary cells, cell lines, and primary leukemia samples for consistent target validation.
Translational & Preclinical Research
- Scientific Value: Demonstrates engraftment of edited human HSPCs in NSG mice, supporting translational continuity from discovery to preclinical validation.
- Operational Value: Provides a streamlined three-day workflow compatible with preclinical timelines for target validation studies.
- Strategic Value: Reduces mechanistic ambiguity in hematopoietic targets, enabling risk-adjusted advancement decisions in oncology and immunology pipelines.
Pipeline & Workflow Integration
This method integrates into the discovery continuum from target identification through lead optimization, enabling rapid functional validation of hematopoietic targets before compound screening.
- Discovery Biology: Supports hypothesis testing and pathway clarification via efficient gene disruption in primary hematopoietic cells.
- Screening: Delivers assay-ready knockout models with high reproducibility and quantitative outputs for reliable compound evaluation.
- Analytics: Generates measurable editing efficiencies through flow cytometry and T7 endonuclease assays, enabling comparative condition analysis.
- Translational Research: Connects discovery to preclinical validation through demonstrated engraftment of edited HSPCs in vivo.
- Enterprise Reuse: Establishes a reusable CRISPR/Cas9 RNP platform applicable across hematopoietic models, reducing redundant protocol development.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation, reduction of mechanistic ambiguity, and high-fidelity gene disruption without DNA integration.
- Operational Value: Standardization, reproducibility, and scalability of gene editing across primary and transformed hematopoietic cells.
- Strategic Value: Improved go/no-go decisions, capital efficiency, and reduced late-stage biological risk in hematologic drug programs.
- Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on rapid, high-efficiency target knockout data.
Implementation Considerations
- Requires expertise in molecular cloning, RNA handling, and electroporation techniques.
- Dependent on access to thermocycler, spectrophotometer, electroporation unit, and flow cytometry for validation.
- Necessitates RNase-free environments and standardized reagent handling to ensure RNP stability and editing efficiency.
- Requires adaptation of guide RNA design and optimization for diverse hematopoietic models and target genes.
- Practical limitation: Efficiency may vary with cell type and target locus, necessitating empirical validation per gene of interest.
Biopharma FAQs
Why is null hypothesis testing important for target validation using CRISPR?
Null hypothesis testing helps determine whether observed gene disruption phenotypes are statistically significant, supporting confident target validation decisions in hematopoietic systems.
How does isolating the independent variable (gene knockout) fit the discovery pipeline?
By using RNP delivery to achieve clean gene knockout without exogenous DNA, the method isolates the effect of gene loss, enabling clear phenotype-to-genotype linkage in target validation.
What quantitative dependent variable measurements enable target assessment?
Flow cytometry measures protein-level loss of target expression (e.g., GFP, CD45), while T7 endonuclease assays quantify DNA cleavage, providing orthogonal readouts for editing efficiency.
Why do replication requirements matter for cross-functional collaboration?
Replication ensures consistent knockout efficiencies across experiments and sites, enabling reliable data sharing between discovery, preclinical, and translational teams.
What statistical analysis capabilities are required before implementing this CRISPR workflow?
Teams require ability to analyze flow cytometry data and calculate cleavage ratios from gel imaging to quantify editing efficiency and assess statistical significance of knockout results.
Chapters in this video
0:05
Title
1:05
sgRNA Fwd Primer Design, DNA Template Synthesis, and ln Vitro Transcription of sgRNA
3:38
Cas9-sgRNA Complexing and Electroporation
5:45
Results: Use of Cas9-sgRNA Electroporation Protocol to Study Efficient Knockout of Target Gene
7:48
Conclusion
